Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,506.48
(
-1.51%
)
US TECH 100
23,484.80
(
-0.99%
)
Dow Jones
45,577.47
(
-0.96%
)
Brent Oil
108.35
(
0.20%
)
Bitcoin
68,617.16
(
1.15%
)
News Focus
News Focus
Post# of 257269
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

ciotera

Send PM Follow Ignore
Followers 8
Posts 512
Boards Moderated 0
Alias Born 08/03/2005

ciotera

Re: oc631 post# 171473

Wednesday, 12/18/2013 12:58:30 PM

Wednesday, December 18, 2013 12:58:30 PM

Post# of 257269

inadvertent error



No, I mean that ABBV does not have a "maximize SVR" positioning strategy. GILD still has the "simplest, safest, shortest, highly-effective interferon and ribavirin free" positioning which is all they need to dominate this market. The only way they can lose some of it is due to pricing/contracting competition.
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today